S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

SXTP 60 Degrees Pharmaceuticals Inc

2.79

0.00 (0.00%)

Pre Market

Last Updated: 18:26:28

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

60 Degrees Pharmaceuticals (NASDAQ:SXTP)
Historical Stock Chart
From Mar 2025 to Apr 2025

Click Here for more 60 Degrees Pharmaceuticals Charts.

60 Degrees Pharmaceuticals (NASDAQ:SXTP)
Historical Stock Chart
From Apr 2024 to Apr 2025

Click Here for more 60 Degrees Pharmaceuticals Charts.

60 Degrees Pharmaceuticals Inc News

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey
Tuesday 22 April 2025 (7 days ago) • GlobeNewswire Inc.

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21
Thursday 10 April 2025 (3 weeks ago) • GlobeNewswire Inc.

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health
Tuesday 8 April 2025 (3 weeks ago) • GlobeNewswire Inc.

60 Degrees Pharmaceuticals Announces 2024 Annual Results
Friday 28 March 2025 (1 month ago) • GlobeNewswire Inc.

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split
Friday 21 February 2025 (2 months ago) • GlobeNewswire Inc.

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®
Wednesday 12 February 2025 (3 months ago) • GlobeNewswire Inc.

60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Friday 7 February 2025 (3 months ago) • GlobeNewswire Inc.

60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Thursday 6 February 2025 (3 months ago) • GlobeNewswire Inc.

60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Friday 31 January 2025 (3 months ago) • GlobeNewswire Inc.

60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Thursday 30 January 2025 (3 months ago) • GlobeNewswire Inc.

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
Wednesday 29 January 2025 (3 months ago) • GlobeNewswire Inc.

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis
Thursday 9 January 2025 (4 months ago) • GlobeNewswire Inc.

More 60 Degrees Pharmaceuticals Inc News Articles

Tempest Minerals

Ora Banda Mining

Firsthand Technology Value (QB)

Exchange Traded

HANetf Procure Space UCI...

Artemis Resources

CleanTech Lithium

Fidelity National Inform...

Laneway Resources

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions